前哨淋巴结活检在高危子宫内膜癌中的应用进展
Advances in the Application of Sentinel Lymph Node Biopsy in High-Risk Endometrial Cancer
摘要: 子宫内膜癌作为危害女性健康的一个重要因素,除了癌症本身对女性健康的影响,手术过程以及术后并发症,都成为影响患者术后生活质量的重要因素,其中系统性淋巴结清扫术作为影响术后生活质量的一个原因,成为了关注点。前哨淋巴结活检作为替代系统性淋巴结清扫术的方案,一方面可以降低术中及术后的并发症发生率,另一方面,可以进行病理超分期,发现更小的病变,如孤立肿瘤细胞和微转移,以指导进一步治疗。前哨淋巴结活检的示踪剂及其注射部位有着较多的探索和研究,常用的示踪剂有吲哚菁绿等,注射部位则包括子宫颈注射及多个部位联合注射等。病理超分期也不局限于传统的伊红苏木精染色联合免疫组化,出现了基于分子检测的一步核酸扩增等方法,以提高检测的速度和准确性。依照前哨淋巴结算法,前哨淋巴结活检在低危子宫内膜癌中有着良好的前景,而对于高危子宫内膜癌,仍需要更多的研究明确其可行性。
Abstract: Endometrial cancer has a huge effect on women’s health. In addition to the impact of cancer itself on women’s health, the surgical process and postoperative complications have become important factors affecting patients’ postoperative quality of life. Systematic lymphadenectomy has become a focus as a reason for affecting the quality of life after surgery. Sentinel lymph node biopsy, as an alternative to systematic lymphadenectomy, can reduce the incidence of complications during and after surgery, and on the other hand, it can be used for pathological ultra-staging to find smaller lesions, such as isolated tumor cells and micrometastasis, to guide further treatment. There are many explorations and researches on the tracers of sentinel lymph node biopsy and their injection sites. The commonly used tracers include indocyanine green, and the injection sites include cervical injection and joint injection of multiple sites. Pathological ultra-staging is not limited to the traditional eosin hematoxylin staining combined with immunohistochemistry, and there are one-step nucleic acid amplification methods based on molecular detection to improve the speed and accuracy of detection. According to the sentinel lymph node algorithm, sentinel lymph node biopsy has a good prospect in low-risk endometrial cancer, but for high-risk endometrial cancer, more research is still needed to clarify its feasibility.
文章引用:王钊松, 李世娇, 夏敏. 前哨淋巴结活检在高危子宫内膜癌中的应用进展[J]. 临床医学进展, 2024, 14(3): 1449-1455. https://doi.org/10.12677/acm.2024.143864

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Lu, K.H. and Broaddus, R.R. (2020) Endometrial Cancer. The New England Journal of Medicine, 383, 2053-2064. [Google Scholar] [CrossRef
[3] Oaknin, A., Bosse, T.J., Creutzberg, C.L., et al. (2022) Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 33, 860-877. [Google Scholar] [CrossRef] [PubMed]
[4] Abu-Rustum, N.R., Yashar, C.M., Bradley, K., et al. (2021) NCCN Guidelines® Insights: Uterine Neoplasms, Version 3. Journal of the National Comprehensive Cancer Network: JNCCN, 19, 888-895. [Google Scholar] [CrossRef] [PubMed]
[5] Gu, Y., Cheng, H., Zong, L., et al. (2020) Operative and Oncological Outcomes Comparing Sentinel Node Mapping and Systematic Lymphadenectomy in Endometrial Cancer Staging: Meta-Analysis with Trial Sequential Analysis. Frontiers in Oncology, 10, Article ID: 580128. [Google Scholar] [CrossRef] [PubMed]
[6] Pölcher, M., Rottmann, M., Brugger, S., et al. (2019) Lymph Node Dissection in Endometrial Cancer and Clinical Outcome: A Population-Based Study in 5546 Patients. Gynecologic Oncology, 154, 65-71. [Google Scholar] [CrossRef] [PubMed]
[7] Zorzato, P.C., Bosco, M., Franchi, M.P., et al. (2021) Sentinel Lymph Node for Endometrial Cancer Treatment: Review of the Literature. Minerva Medica, 112, 70-80. [Google Scholar] [CrossRef
[8] Geppert, B., Lönnerfors, C., Bollino, M., et al. (2018) Sentinel Lymph Node Biopsy in Endometrial Cancer-Feasibility, Safety and Lymphatic Complications. Gynecologic Oncology, 148, 491-498. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, C.Y., Elias, K.M., Howitt, B.E., et al. (2017) Sentinel Lymph Node Mapping Reduces Practice Pattern Variations in Surgical Staging for Endometrial Adenocarcinoma: A before and after Study. Gynecologic Oncology, 145, 248-255. [Google Scholar] [CrossRef] [PubMed]
[10] Matsuo, K., Klar, M., Khetan, V.U., et al. (2022) Sentinel Lymph Node Biopsy for Stage II Endometrial Cancer: Recent Utilization and Outcome in the United States. Gynecologic Oncology, 164, 46-52. [Google Scholar] [CrossRef] [PubMed]
[11] Glaser, G., Dinoi, G., Multinu, F., et al. (2021) Reduced Lymphedema after Sentinel Lymph Node Biopsy versus Lymphadenectomy for Endometrial Cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 31, 85-91. [Google Scholar] [CrossRef] [PubMed]
[12] Zhai, L., Zhang, X., Cui, M., et al. (2021) Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review. Frontiers in Oncology, 11, Article ID: 701758. [Google Scholar] [CrossRef] [PubMed]
[13] Marchocki, Z., Cusimano, M.C. and Ferguson, S.E. (2022) Sentinel Lymph Node Biopsy in High-Grade Endometrial Cancer. American Journal of Obstetrics and Gynecology, 226, 867-868. [Google Scholar] [CrossRef] [PubMed]
[14] Marchocki, Z., Cusimano, M.., Clarfield, L., et al. (2021) Sentinel Lymph Node Biopsy in High-Grade Endometrial Cancer: A Systematic Review and Meta-Analysis of Performance Characteristics. American Journal of Obstetrics and Gynecology, 225, 367.e1-367.e39.
[15] Ye, L., Li, S., Lu, W., et al. (2019) A Prospective Study of Sentinel Lymph Node Mapping for Endometrial Cancer: Is It Effective in High-Risk Subtypes? The Oncologist, 24, E1381-E1387. [Google Scholar] [CrossRef] [PubMed]
[16] Nagar, H., Wietek, N., Goodall, R.J., et al. (2021) Sentinel Node Biopsy for Diagnosis of Lymph Node Involvement in Endometrial Cancer. Cochrane Database of Systematic Reviews, 6, CD013021. [Google Scholar] [CrossRef
[17] Zuo, J., Wu, L.Y., Cheng, M., et al. (2019) Comparison Study of Laparoscopic Sentinel Lymph Node Mapping in Endometrial Carcinoma Using Carbon Nanoparticles and Lymphatic Pathway Verification. Journal of Minimally Invasive Gynecology, 26, 1125-1132. [Google Scholar] [CrossRef] [PubMed]
[18] Backes, F.J., Cohen, D., Salani, R., et al. (2019) Prospective Clinical Trial of Robotic Sentinel Lymph Node Assessment with Isosulfane Blue (ISB) and Indocyanine Green (ICG) in Endometrial Cancer and the Impact of Ultrastaging (NCT01818739). Gynecologic Oncology, 153, 496-499. [Google Scholar] [CrossRef] [PubMed]
[19] Cabrera, S., Barahona-Orpinell, M., Almansa-González, C., et al. (2021) Combined Use of ICG and Technetium Does Not Improve Sentinel Lymph Node Detection in Endometrial Cancer: Results of the COMBITEC Study. Gynecologic Oncology, 162, 32-37. [Google Scholar] [CrossRef] [PubMed]
[20] Cusimano, M.C., Vicus, D., Pulman, K., et al. (2021) Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate-and High-Grade Endometrial Cancer Staging. JAMA Surgery, 156, 157-164. [Google Scholar] [CrossRef] [PubMed]
[21] Maramai, M., Achilarre, M.T., Aloisi, A., et al. (2021) Cervical Re-Injection of Indocyanine Green to Improve Sentinel Lymph Node Detection in Endometrial Cancer. Gynecologic Oncology, 162, 38-42. [Google Scholar] [CrossRef] [PubMed]
[22] Farazestanian, M., Yousefi, Z., Zarifmahmoudi, L., et al. (2019) Concordance between Intracervical and Fundal Injections for Sentinel Node Mapping in Patients with Endometrial Cancer? A Study Using Intracervical Radiotracer and Fundal Blue Dye Injections. Clinical Nuclear Medicine, 44, E123-E127. [Google Scholar] [CrossRef
[23] Ditto, A., Casarin, I., Pinelli, C., et al. (2020) Hysteroscopic versus Cervical Injection for Sentinel Node Detection in Endometrial Cancer: A Multicenter Prospective Randomised Controlled Trial from the Multicenter Italian Trials in Ovarian Cancer (MITO) Study Group. European Journal of Cancer (Oxford, England: 1990), 140, 1-10. [Google Scholar] [CrossRef] [PubMed]
[24] Persson, J., Geppert, B., Lönnerfors, C., et al. (2017) Description of a Reproducible Anatomically Based Surgical Algorithm for Detection of Pelvic Sentinel Lymph Nodes in Endometrial Cancer. Gynecologic Oncology, 147, 120-125. [Google Scholar] [CrossRef] [PubMed]
[25] Persson, J., Salehi, S., Bollino, M., et al. (2019) Pelvic Sentinel Lymph Node Detection in High-Risk Endometrial Cancer (SHREC-Trial)—The Final Step towards a Paradigm Shift in Surgical Staging. European Journal of Cancer (Oxford, England: 1990), 116, 77-85. [Google Scholar] [CrossRef] [PubMed]
[26] García Pineda, V., Hernández Gutiérrez, A., Gracia Segovia, M., et al. (2020) Low-Volume Nodal Metastasis in Endometrial Cancer: Risk Factors and Prognostic Significance. Journal of Clinical Medicine, 9, Article No. 1999. [Google Scholar] [CrossRef] [PubMed]
[27] Ghoniem, K., Larish, A.M., Dinoi, G., et al. (2021) Oncologic Outcomes of Endometrial Cancer in Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: An International Multi-Institutional Study. Gynecologic Oncology, 162, 590-598. [Google Scholar] [CrossRef] [PubMed]
[28] Backes, F.J., Felix, A.S., Plante, M., et al. (2021) Sentinel Lymph Node (SLN) Isolated Tumor Cells (ITCs) in Otherwise Stage I/II Endometrioid Endometrial Cancer: to Treat or Not to Treat? Gynecologic Oncology, 161, 347-352. [Google Scholar] [CrossRef] [PubMed]
[29] Concin, N., Matias-Guiu, X., Vergote, I., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. Radiotherapy and Oncology, 154, 327-353. [Google Scholar] [CrossRef] [PubMed]
[30] Sims, T.T. and Boruta, D.M. (2021) Sentinel Lymph Node Isolated Tumor Cells in Early Staged Endometrioid Endometrial Cancer: Utility or Futility? Gynecologic Oncology, 161, 331-332. [Google Scholar] [CrossRef] [PubMed]
[31] Goebel, E.A., St Laurent, J.D., Nucci, M.R., et al. (2020) Retrospective Detection of Isolated Tumor Cells by Immunohistochemistry in Sentinel Lymph Node Biopsy Performed for Endometrial Carcinoma: Is There Clinical Significance? International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 30, 291-298. [Google Scholar] [CrossRef] [PubMed]
[32] Bogani, G., Mariani, A., Paolini, B., et al. (2019) Low-Volume Disease in Endometrial Cancer: The Role of Micrometastasis and Isolated Tumor Cells. Gynecologic Oncology, 153, 670-675. [Google Scholar] [CrossRef] [PubMed]
[33] Diestro, M.D., Berjón, A., Zapardiel, I., et al. (2021) One-Step Nucleic Acid Amplification (OSNA) of Sentinel Lymph Node in Early-Stage Endometrial Cancer: Spanish Multicenter Study (ENDO-OSNA). Cancers, 13, Article No. 4465. [Google Scholar] [CrossRef] [PubMed]
[34] Kosťun, J., Pešta, M., Sláma, J., et al. (2019) One-Step Nucleic Acid Amplification vs Ultrastaging in the Detection of Sentinel Lymph Node Metastasis in Endometrial Cancer Patients. Journal of Surgical Oncology, 119, 361-369. [Google Scholar] [CrossRef] [PubMed]
[35] Togami, S., Ushiwaka, T., Kitazono, I., et al. (2022) One-Step Nucleic Acid Amplification (OSNA) Assay for Detecting Lymph Node Metastasis in Cervical and Endometrial Cancer: A Preliminary Study. Journal of Gynecologic Oncology, 33, E11. [Google Scholar] [CrossRef] [PubMed]
[36] Angeles, M.A., Martínez-Gómez, C., Migliorelli, F., et al. (2018) Novel Surgical Strategies in the Treatment of Gynecological Malignancies. Current Treatment Options in Oncology, 19, Article No. 73. [Google Scholar] [CrossRef] [PubMed]
[37] Pineda, V.G., Zapardiel, I., Gracia, M., et al. (2021) Avoiding Full Lymphadenectomies in Intermediate-and High-Risk Endometrial Cancer by Sentinel Lymph Node Biopsy Implementation. Frontiers in Oncology, 11, Article ID: 654285. [Google Scholar] [CrossRef] [PubMed]
[38] Pijnenborg, J.M.A., Reijnen, C., Vergeldt, T.F.M., et al. (2020) Optimizing the Treatment Algorithm for Sentinel Lymph Node Mapping in Endometrial Cancer. Seminars in Oncology, 47, 138-143. [Google Scholar] [CrossRef] [PubMed]
[39] Kogan, L., Matanes, E., Wissing, M., et al. (2020) The Added Value of Sentinel Node Mapping in Endometrial Cancer. Gynecologic Oncology, 158, 84-91. [Google Scholar] [CrossRef] [PubMed]
[40] Torrent, A., Amengual, J., Sampol, C.M., et al. (2022) Sentinel Lymph Node Biopsy in Endometrial Cancer: Dual Injection, Dual Tracer—A Multidisciplinary Exhaustive Approach to Nodal Staging. Cancers, 14, Article No. 929. [Google Scholar] [CrossRef] [PubMed]